(File photo downloaded from Costco’s website) South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease treatment Stelara launched two weeks ago, at US retail giant Costco to bite into the original dr
A Celltrion researcher Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosimilar market with their robust R&D capabilities and fast-tracked clinical trial process.The two South Korean companies ha
Celltrion's third plant in Songdo, Incheon Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, following approvals in South Korea in December and in the US last month.Avtozma is an interleukin inhibit
South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steqeyma (ustekinumab) in the US, the biosimilar of autoimmune disease treatment Stelara.Based on the global Phase 3 results, Celltrion can sell Steqe
Researchers at a Celltrion R&D lab (Courtesy of Celltrion) Celltrion Inc. on Tuesday launched its contract development and manufacturing organization unit Celltrion BioSolutions Co. in its foray into the CDMO market. As a newcomer to the field, it will produce a wider range of products than
A bird's-eye view of Celltrion's Songdo campus in Incheon, South Korea Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) recommended approval of the drugs. Once approved, the biosimilars will expand t
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma and chronic idiopathic urticaria treatment Xolair, the company said on Monday. With this approval, Celltrion can sell Omlyclo in Canada for all
Celltrion founder and Chairman Seo Jung-jin speaks at Korea Investment Week 2024, hosted by the Korea Economic Daily, on Sept. 11, 2024 South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (CDMO) plant
Remsima obtained FDA approval in 2016 Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this year to become the first Korean drug to do so. Remsima raked in 979.7 billion won in sales in the first
South Korea's Celltrion Inc. said on Friday that it completed its acquisition of iQone Healthcare Switzerland, a Swiss pharmaceutical distributor, to begin direct sales in Switzerland.The acquisition, valued at approximately 30 billion won ($21 million), was conducted through Celltrion’s
South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.The company introduced Steqeyma in Germany on November 1, promoting the product’s competitive edge to local medical professionals, including